Versartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentation...
September 07 2017 - 4:05PM
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused
biopharmaceutical company that is developing somavaratan, a novel,
long-acting form of recombinant human growth hormone (rhGH) for
growth hormone deficiency (GHD), announced that somavaratan data
will be featured in an oral presentation and three posters during
the 10th International Meeting of Pediatric Endocrinology (IMPE),
to be held September 14-17, in Washington D.C. The abstracts are
available on the IMPE 2017 website.
“IMPE brings together pediatric endocrine
specialists from around the world every four years, and serves as a
great opportunity to further highlight the depth of our long-term
experience with somavaratan treatment in children with GHD,” said
Colin Hislop, MD, Chief Development Officer. “We now have over 400
patients exposed to somavaratan, some of whom have been on our
product for four years. We have built the largest data set of any
long-acting growth hormone currently in development for pediatric
patients, and are pleased with the results we have seen to date.
With Phase 3 topline results expected around the end of September
and plans to complete enrollment of our Phase 3 trial in Japan
before year end, somavaratan is on a solid path to be the first to
market for pediatric GHD among the new, long-acting growth hormone
candidates in development.”
ORAL PRESENTATION (Growth and GH/IGF Axis #2 Free
Communication Session)Saturday, September 16, 2017
– 7:30 – 8:30 AMFC58 - 3-Year Update of the Phase 2a and
Long-term Safety Studies (VERTICAL and VISTA) of Somavaratan
(VRS-317), a Long-acting rhGH for the Treatment of Pediatric
Growth
POSTER PRESENTATION (Poster Session
#1)Thursday, September 14, 2017 – 5:45 – 6:45
PMP1-820 - Dynamic Changes in IGF-I During Somavaratan
Therapy in Pediatric Subjects with Growth Hormone Deficiency from
the VISTA Long-Term Safety Study
POSTER PRESENTATION (Poster Session
#2)Friday September 15, 2017 – 11:30 AM – 12:30
PMP2-824 - Change in Body Mass Index During Somavaratan
Therapy in Pediatric Subjects with Growth Hormone Deficiency in the
VISTA Long-Term Safety Study
LATE-BREAKING POSTER PRESENTATION (Poster Session
#3)Saturday, September 16, 2017 – 12:00 PM – 1:00
PMP3-857 - Relative Changes in Bone Age and Linear Growth
in Children With Growth Hormone Deficiency (GHD) Treated With
Twice-Monthly Somavaratan (VRS-317)
About Versartis, Inc.
Versartis, Inc. is an endocrine-focused
biopharmaceutical company initially developing somavaratan, a
novel, long-acting form of recombinant human growth hormone in
late-stage clinical trials for the treatment of GHD in children and
adults. Somavaratan is intended to reduce the burden of daily
injection therapy by requiring significantly fewer injections,
potentially improving adherence and, therefore, treatment
outcomes.
For more information on Versartis, visit
www.versartis.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding our intentions or current
expectations concerning, among other things, plans and timing of
our clinical trials and the potential for eventual regulatory
approval of somavaratan. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated. We discuss many of these risks
in greater detail under the heading "Risk Factors" contained in our
Annual Report on Form 10-K for the year ended December 31, 2016 and
in our Quarterly Report on Form 10-Q for the three months ended
June 30, 2017 which are on file with the Securities and Exchange
Commission (SEC). Forward-looking statements are not guarantees of
future performance, and our actual results may differ materially
from the forward-looking statements contained in this press
release. Any forward-looking statements that we make in this press
release speak only as of the date of this press release and we
assume no obligation to update them after the date of this press
release.
Contacts:
Corporate Communications:
Christine Labaree
Corporate Affairs
(650) 600-1697
clabaree@versartis.com
Investors:
David Burke
Director, Investor Relations
(650) 516-2703
dburke@versartis.com
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Apr 2023 to Apr 2024